Literature DB >> 16824852

Conjugated equine estrogens and peripheral arterial disease risk: the Women's Health Initiative.

Judith Hsia1, Michael H Criqui, David M Herrington, Joann E Manson, Lieling Wu, Susan R Heckbert, Matthew Allison, Mary McGrae McDermott, Jennifer Robinson, Kamal Masaki.   

Abstract

BACKGROUND: Estradiol reduced progression of ultrasonographic carotid disease in a randomized trial. No trials of unopposed estrogen for prevention of lower extremity arterial disease or aortic aneurysm have been conducted.
METHODS: The Estrogen Alone trial randomized 10739 postmenopausal women with prior hysterectomy, mean age 63.6 +/- 7.3 years, to conjugated equine estrogens (CEE 0.625 mg/d) or placebo and documented health outcomes over an average of 7.1 +/- 1.6 years.
RESULTS: A trend toward increased risk of peripheral arterial events with CEE was observed (hazard ratio [HR] 1.32, 95% CI 0.99-1.77). Carotid arterial events (HR 1.19, 95% CI 0.82-1.74), lower extremity arterial events (HR 1.41, 95% CI 0.86-2.32), and abdominal aortic aneurysm (HR 2.40, 95% CI 0.92-6.23) were more frequent, but not individually significant, in the CEE group. However, the composite of lower extremity arterial disease/abdominal aortic aneurysm was significantly more frequent among women assigned to CEE (HR 1.63, 95 % CI 1.05-2.51). In subgroup analyses, no clear pattern of risk with CEE was apparent by age or by time since menopause.
CONCLUSIONS: Unopposed CEE conferred no protection against peripheral arterial disease among generally healthy postmenopausal women; in fact, there was a suggestion of increased risk.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16824852     DOI: 10.1016/j.ahj.2005.09.005

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  22 in total

Review 1.  Cardiovascular disease and primary ovarian insufficiency.

Authors:  Melissa Wellons
Journal:  Semin Reprod Med       Date:  2011-10-03       Impact factor: 1.303

Review 2.  Gender Differences in Peripheral Vascular Disease.

Authors:  Kristofer Schramm; Paul J Rochon
Journal:  Semin Intervent Radiol       Date:  2018-04-05       Impact factor: 1.513

Review 3.  Consideration of Sex Differences in Design and Reporting of Experimental Arterial Pathology Studies-Statement From ATVB Council.

Authors:  Peggy Robinet; Dianna M Milewicz; Lisa A Cassis; Nicholas J Leeper; Hong S Lu; Jonathan D Smith
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-01-04       Impact factor: 8.311

4.  The relative importance of systolic versus diastolic blood pressure control and incident symptomatic peripheral artery disease in women.

Authors:  Tiffany M Powell; Robert J Glynn; Julie E Buring; Mark A Creager; Paul M Ridker; Aruna D Pradhan
Journal:  Vasc Med       Date:  2011-07-05       Impact factor: 3.239

Review 5.  Vascular effects of estrogenic menopausal hormone therapy.

Authors:  Ossama M Reslan; Raouf A Khalil
Journal:  Rev Recent Clin Trials       Date:  2012-02

6.  Loss of receptor activity-modifying protein 3 exacerbates cardiac hypertrophy and transition to heart failure in a sex-dependent manner.

Authors:  Cordelia J Barrick; Patricia M Lenhart; Ryan T Dackor; Elizabeth Nagle; Kathleen M Caron
Journal:  J Mol Cell Cardiol       Date:  2011-11-04       Impact factor: 5.000

7.  Estrogen, vascular estrogen receptor and hormone therapy in postmenopausal vascular disease.

Authors:  Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2013-10-04       Impact factor: 5.858

8.  Instrumental variables I: instrumental variables exploit natural variation in nonexperimental data to estimate causal relationships.

Authors:  Jeremy A Rassen; M Alan Brookhart; Robert J Glynn; Murray A Mittleman; Sebastian Schneeweiss
Journal:  J Clin Epidemiol       Date:  2009-04-08       Impact factor: 6.437

Review 9.  Vascular actions of estrogens: functional implications.

Authors:  Virginia M Miller; Sue P Duckles
Journal:  Pharmacol Rev       Date:  2008-06-25       Impact factor: 25.468

10.  Submaximal exercise coronary artery flow increases in postmenopausal women without coronary artery disease after estrogen and atorvastatin.

Authors:  Chirapa Puntawangkoon; Tim M Morgan; David M Herrington; Craig A Hamilton; W Gregory Hundley
Journal:  Menopause       Date:  2010 Jan-Feb       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.